Vaso-occlusive Crisis clinical trials at UC Irvine
1 research study open to eligible people
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
open to eligible people ages 12 years and up
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Irvine, California and other locations
Our lead scientists for Vaso-occlusive Crisis research studies include Zahra Pakbaz, MD.